A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases

Oncology Research

Volumn 19, Issue 6, 2011, Pages 287-295

  El Mabhouh, A A ^b   Nation, P N ^a   Abele, J T ^a   Riauka, T ^a   Postema, E ^a   McEwan, A J B ^a   Mercer, John R ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b NONE

Author keywords

Bisphosphonate; Bone metastases; Breast cancer; Gemcitabine; MDA MB 231

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CREATININE; GEMCITABINE; TECHNETIUM 99M; ANTINEOPLASTIC ANTIMETABOLITE; CALCIUM; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER CELL; CANCER SIZE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; FEMUR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMERUS; MOUSE; NONHUMAN; PERIOSTEUM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BONE TUMOR; BREAST TUMOR; CHEMISTRY; DISEASE MODEL; DRUG DELIVERY SYSTEM; INTRALESIONAL DRUG ADMINISTRATION; METASTASIS; NUDE MOUSE; PATHOLOGY; SCINTISCANNING; TUMOR CELL CULTURE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; CALCIUM; CREATININE; DEOXYCYTIDINE; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, INBRED BALB C; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; TECHNETIUM; TUMOR CELLS, CULTURED;

EID: 80051642446     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X13021877989874     Document Type: Article

References (30)

1. Akhtari, M.; Mansuri, J.; Newman, K. A.; Guise, T. M.; Seth, P. Biology of breast cancer bone metastasis. Cancer Biol. Ther. 7:3-9; 2008.
2. Kingsley, L. A.; Fournier, P. G.; Chirgwin, J. M.; Guise, T. A. Molecular biology of bone metastasis. Mol. Cancer Ther. 6:2609-2617; 2007.
3. Clark, J. C.; Dass, C. R.; Choong, P. F. Current and future treatments of bone metastases. Expert Opin. Emerg. Drugs 13:609-627; 2008.
4. Rubens, R. D. Bone metastases - the clinical problem. Eur. J. Cancer 34:210-213; 1998.
5. Green, J. R. Antitumor effects of bisphosphonates. Cancer 97(Suppl.):840-847; 2003.
6. Stresing, V.; Daubiné, F.; Benzaid, I.; Mönkkönen, H.; Clézardin, P. Bisphosphonates in cancer therapy. Cancer Lett. 257:16-35; 2007.
7. Daubiné, F.; Le Gall, C.; Gasser, J.; Green, J.; Clézardin, P. Antitumor effects of clinical dosing regimens of bisvivo phosphonates in experimental breast cancer bone metastasis. J. Natl. Cancer Inst. 99:322-330; 2007.
8. Hiraga, T.; Williams, P. J.; Mundy, G. R.; Yoneda, T. The bisphosphonate ibandronate promotes apoptosis in MDAin MB-231 human breast cancer cells in bone metastasis. Cancer Res. 61:4418-4424; 2001.
9. Machado, M.; Cruz, L. S.; Tannus, G.; Fonseca, M. Efficacy of clodronate, pamidronate, and zoledronate in ducing morbidity and mortality in cancer patients with bone metastasis: A meta-analysis of randomized clinical trials. Clin. Ther. 31:962-979; 2009.
10. Hillnerr, B. E.; Ingle, J. N.; Berenson, J. R.; Janjan, N. A.; Albain, K. S.; Lipton, A.; Yee, G.; Biermann, J. S.; Chlebowski, R. T.; Pfister, D. G.; for the American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology guidelines on the role of bisphosphonates in breast cancer. J. Clin. Oncol. 18:1378-1391; 2000.
11. Gittens, S. A.; Bansal, G.; Kucharski, C.; Borden, M.; Uludag, H. Imparting mineral affinity to fetuin by bisphosphonate conjugation: A comparison of three bisphosphonate conjugation schemes. Mol. Pharm. 2:392-406; 2005.
12. Herczegh, P.; Buxton, T. B.; McPherson, 3rd, J. C.; Kovaaposcs-Kulyassa, A.; Brewer, P. D.; Sztaricskai, F.; Stroebel, G. G.; Plowman, K. M.; Farcasiu, D.; Hartmann, J. F. Osteoadsorptive bisphosphonate derivatives of fluorduced oquinolone antibacterials. J. Med. Chem. 45:2338-2341; 2002.
13. Hosain, F.; Spencer, R. P.; Couthon, H. M.; Sturtz, G. L. Targeted delivery of antineoplastic agent to bone: Biodistribution studies of technetium-99m-labeled gem-bisphosexploring phonate conjugate of methotrexate. J. Nucl. Med. 37:105-107; 1996.
14. 99mTc-labeled gemcitabine bisphosphonate drug reconjugate as a probe to assess the potential for targeted metastachemotherapy of metastatic bone cancer. Nucl. Med. Biol. 33:715-722; 2006.
15. Mundy, G. R.; Yoneda, T.; Hiraga, T. Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment. Semin. Oncol. 28:35-44; 2001.
16. Jones, S. E. Metastatic breast cancer: The treatment challenge. Clin. Breast Cancer 8:224-233; 2008.
17. Mauri, D.; Polyzos, N. P.; Salanti, G.; Pavlidis, N.; Ioannidis, J. P. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J. Natl. Cancer Inst. 100:1780-1791; 2008.
18. El-Mabhouh, A.; Angelov, C.; McEwan, A.; Jia, G.; Mercer, J. Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer. Cancer Biother. Radiopharm. 19: 627-640; 2004.
19. Yoneda, T.; Williams, P. J.; Hiraga, T.; Niewolna, M.; Nishimura, R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Miner. Res. 16:1486-1495; 2001.
20. Käkönen, S-M.; Mundy, G. R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97(S3):834-839; 2003.
21. Veerman, G.; Ruiz van Haperen, V. W. T.; Vermorken, J. B.; Noordhuis, P.; Braakhuis, B. J.; Pinedo, H. M.; Peters, G. J. Antitumor activity of prolonged as compared with bolus administration of 2,2-difluorodeoxycytidine in bisvivo against murine colon tumors. Cancer Chemother. Pharmacol. 38:335-342; 1996.
22. Blackstein, M.; Vogel, C. L.; Ambinder, R.; Cowan, J.; Iglesias, J.; Melemed, A. Gemcitabine as first-line therapy MDAin patients with metastatic breast cancer: A Phase II trial. Oncology 62:2-8; 2002.
23. Kozlow, W.; Guise, T. A.; Szeto, C. C.; Chow, K. M. Nephrotoxicity related to new therapeutic compounds. Ren. Fail. 27:329-333; 2005.
24. Hirschberg, R. Nephrotoxicity of third-generation intravenous bisphosphonates. Toxicology 196:165-167; 2004.
25. Grant, F. D.; Fahey, F. H.; Packard, A. B.; Davis, R. T.; Alavi, A.; Treves, S. T. Skeletal PET with 18F-fluoride: Applying new technology to an old tracer. J. Nucl. Med. 49:68-78; 2008.
26. Even-Sapire, E.; Mishani, E.; Flusser, G.; Metser, U. 18F- Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin. Nucl. Med. 37:462-469; 2007.
27. Serafini, A. N. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q. J. Nucl. Med. 45:91-99; 2001.
28. Liepe, K.; Kropp, J.; Runge, R.; Kotzerke, J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br. J. Cancer 89:625-629; 2003.
29. El-Mabhouh, A. A.; Mercer, J. R. 188Re-labelled gemcitabine/ bisphosphonate (Gem/BP): A multi-functional, bonespecific agent as a potential treatment for bone metastases. Eur. J. Nucl. Med. Mol. Imaging 35:1240-1248; 2008.
30. Morgan, M. A.; Parsels, L. A.; Maybaum, J.; Lawrence, T. S. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy. Clin. Cancer Res. 14: 6744-6750; 2008.